Owen S M, Ellenberger D, Rayfield M, Wiktor S, Michel P, Grieco M H, Gao F, Hahn B H, Lal R B
Retrovirus Diseases Branch, Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
J Virol. 1998 Jul;72(7):5425-32. doi: 10.1128/JVI.72.7.5425-5432.1998.
Several members of the seven-transmembrane chemokine receptor family have been shown to serve, with CD4, as coreceptors for entry by human immunodeficiency virus type 1 (HIV-1). While coreceptor usage by HIV-1 primary isolates has been studied by several groups, there is only limited information available concerning coreceptor usage by primary HIV-2 isolates. In this study, we have analyzed coreceptor usage of 15 primary HIV-2 isolates, using lymphocytes from a donor with nonfunctional CCR5 (CCR5 -/-; homozygous 32-bp deletion). Based on the infections of PBMCs, seven of these primary isolates had an absolute requirement for CCR5 expression, whereas the remaining eight exhibited a broader coreceptor usage. All CCR5-requiring isolates were non-syncytium inducing, whereas isolates utilizing multiple coreceptors were syncytium inducing. Blocking experiments using known ligands for chemokine receptors provided indirect evidence for additional coreceptor utilization by primary HIV-2 isolates. Analysis of GHOST4 cell lines expressing various chemokine receptors (CCR1, CCR2b, CCR3, CCR4, CCR5, CXCR4, BONZO, and BOB) further defined specific coreceptor usage of primary HIV-2 isolates. The receptors used included CXCR4, CCR1-5, and the recently described receptors BONZO and BOB. However, the efficiency at which the coreceptors were utilized varied greatly among the various isolates. Analysis of V3 envelope sequences revealed no specific motif that correlated with coreceptor usage. Our data demonstrate that primary HIV-2 isolates are capable of using a broad range of coreceptors for productive infection in vitro. Additionally, our data suggest that expanded coreceptor usage by HIV-2 may correlate with disease progression.
七跨膜趋化因子受体家族的几个成员已被证明可与CD4一起作为1型人类免疫缺陷病毒(HIV-1)进入细胞的共受体。虽然几个研究小组已对HIV-1原始分离株的共受体使用情况进行了研究,但关于HIV-2原始分离株共受体使用情况的信息却很有限。在本研究中,我们使用来自一名CCR5功能缺失供体(CCR5 -/-;纯合32-bp缺失)的淋巴细胞,分析了15株HIV-2原始分离株的共受体使用情况。基于外周血单核细胞(PBMC)的感染情况,这些原始分离株中有7株绝对需要CCR5表达,而其余8株则表现出更广泛的共受体使用情况。所有需要CCR5的分离株均不具有诱导合胞体形成的能力,而利用多种共受体的分离株具有诱导合胞体形成的能力。使用趋化因子受体已知配体的阻断实验为HIV-2原始分离株额外使用共受体提供了间接证据。对表达各种趋化因子受体(CCR1、CCR2b、CCR3、CCR4、CCR5、CXCR4、BONZO和BOB)的GHOST4细胞系进行分析,进一步明确了HIV-2原始分离株的特定共受体使用情况。所使用的受体包括CXCR4、CCR1 - 5以及最近描述的受体BONZO和BOB。然而,不同分离株对共受体的利用效率差异很大。对V3包膜序列的分析未发现与共受体使用相关的特定基序。我们的数据表明,HIV-2原始分离株在体外能够使用多种共受体进行有效感染。此外,我们的数据表明,HIV-2共受体使用范围的扩大可能与疾病进展相关。